Quantcast

Industry news that matters to you.  Learn more

Biomarkers Changing Clinical Medicine

The pace of biomarker development is accelerating as investigators report new studies on cancer, diabetes, Alzheimer disease, and other conditions in which the evaluation and isolation of workable markers is prominently featured. CHI’s “ADAPT” meeting, to be held later this month, will profile various new strategies being developed by both the academic and private sectors.

Critical Health Unveils a Biomarker for Diabetic Retinopathy Progression at the EuRetina Congress in Paris

Critical Health, a provider of innovative decision support software for ophthalmology, will showcase at the EuRetina Congress in Paris, France (Booth 222B). Recently granted a European IT Excellence Award, Retmarker allows physicians to have a more precise source of information, which is not prone to errors related to the complexity in the estimations of lesion areas present in each subfield of the retinography (color fundus photograph).

Pacific Biomarkers Launches New Website

Pacific Biomarkers, Inc., a provider of biomarker laboratory services to the pharmaceutical, biotechnology and diagnostics industries, unveiled its new website on Friday, July 23. The site, www.PacBio.com, incorporates numerous features to make browsing a more fruitful experience for the Company’s current and potential customers and investors.

Multiple biomarker index useful only in asymptomatic patients with mild atherosclerosis

A multiple biomarker index, one that includes markers of inflammation, is only modestly associated with increased risks of coronary heart disease and cardiovascular disease in asymptomatic patients, according to the results of a new study [1]. The increased risk of events for patients with a biomarker score above the median occurs mainly in those with a mild amount of existing atherosclerosis, according to investigators.